Haefeli WE - Search Results

1

Platelet surface activation markers after DDAVP infusion in healthy subjects.

Tsakiris DA, Haefeli WE, Linder L, Steiner B, Marbet GA. Tsakiris DA, et al. Among authors: haefeli we. Thromb Haemost. 1995 Sep;74(3):991-2. Thromb Haemost. 1995. PMID: 8571336 No abstract available.

2

Acute von Willebrand factor secretion from the endothelium in vivo: assessment through plasma propeptide (vWf:AgII) Levels.

Vischer UM, Ingerslev J, Wollheim CB, Mestries JC, Tsakiris DA, Haefeli WE, Kruithof EK. Vischer UM, et al. Among authors: haefeli we. Thromb Haemost. 1997 Feb;77(2):387-93. Thromb Haemost. 1997. PMID: 9157601

3

Circulating cell adhesion molecules and endothelial markers before and after transluminal angioplasty in peripheral arterial occlusive disease.

Tsakiris DA, Tschöpl M, Jäger K, Haefeli WE, Wolf F, Marbet GA. Tsakiris DA, et al. Among authors: haefeli we. Atherosclerosis. 1999 Jan;142(1):193-200. doi: 10.1016/s0021-9150(98)00175-0. Atherosclerosis. 1999. PMID: 9920521

4

Neurokinin-1 receptor antagonist R116301 inhibits substance P-induced venodilation.

Romerio SC, Linder L, Haefeli WE. Romerio SC, et al. Among authors: haefeli we. Clin Pharmacol Ther. 1999 Nov;66(5):522-7. doi: 10.1016/S0009-9236(99)70016-0. Clin Pharmacol Ther. 1999. PMID: 10579480 Clinical Trial.

5

Auditory and electroencephalographic effects of midazolam and alpha-hydroxy-midazolam in healthy subjects.

Hotz MA, Ritz R, Linder L, Scollo-Lavizzari G, Haefeli WE. Hotz MA, et al. Among authors: haefeli we. Br J Clin Pharmacol. 2000 Jan;49(1):72-9. doi: 10.1046/j.1365-2125.2000.00104.x. Br J Clin Pharmacol. 2000. PMID: 10606840 Free PMC article. Clinical Trial.

6

Subconstrictor doses of neuropeptide Y potentiate alpha 1-adrenergic venoconstriction in vivo.

Linder L, Lautenschlager BM, Haefeli WE. Linder L, et al. Among authors: haefeli we. Hypertension. 1996 Sep;28(3):483-7. doi: 10.1161/01.hyp.28.3.483. Hypertension. 1996. PMID: 8794837

7

Quinaprilat induces arterial vasodilation mediated by nitric oxide in humans.

Haefeli WE, Linder L, Lüscher TF. Haefeli WE, et al. Hypertension. 1997 Oct;30(4):912-7. doi: 10.1161/01.hyp.30.4.912. Hypertension. 1997. PMID: 9336392

8

Pharmacokinetics and pharmacodynamics of clomethiazole after oral and rectal administration in healthy subjects.

Rätz AE, Schlienger RG, Linder L, Langewitz W, Haefeli WE. Rätz AE, et al. Among authors: haefeli we. Clin Ther. 1999 May;21(5):829-40. doi: 10.1016/s0149-2918(99)80005-8. Clin Ther. 1999. PMID: 10397378 Clinical Trial.

9

Neuropeptide Y in human hand veins: pharmacologic characterization and interaction with cyclic guanosine monophosphate-dependent venodilators in vivo.

Peduzzi P, Simper D, Linder L, Strobel WM, Haefeli WE. Peduzzi P, et al. Among authors: haefeli we. Clin Pharmacol Ther. 1995 Dec;58(6):675-83. doi: 10.1016/0009-9236(95)90024-1. Clin Pharmacol Ther. 1995. PMID: 8529333

10

Role of nitric oxide in the regulation of the mechanical properties of peripheral conduit arteries in humans.

Joannides R, Richard V, Haefeli WE, Benoist A, Linder L, Lüscher TF, Thuillez C. Joannides R, et al. Among authors: haefeli we. Hypertension. 1997 Dec;30(6):1465-70. doi: 10.1161/01.hyp.30.6.1465. Hypertension. 1997. PMID: 9403568

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

589 results

Search Page

Filters